Two-dose therapy for S. aureus bloodstream infections on par with standard treatment

A National Institutes of Health (NIH)-supported clinical trial has found that the outcome of treating complicated Staphylococcus aureus bloodstream infections with two intravenous (IV) doses of the antibiotic dalbavancin seven days apart is just as good as daily IV doses of conventional antibiotics over four to six weeks.

This article was originally published on MedicalXpress.com

You may also be interested in:

Read More:

Lawyers Lookup